For all the attention on U.S.-China AI competition, new studies point to China's rapid rise in biotechnology, especially for ...

Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

With finite natural resources and a growing demand for food, the world must find ways to overcome this challenge. One ...

Brooklyn's business park in Sunset Park, Industry City, continues to see tenant demand. Biotech firms Cresilon and Rumi ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...